Anything exciting on the conference call? | ACAD Message Board Posts


ACADIA Pharmaceuticals Inc.

  ACAD website

ACAD   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  19600 of 19609  at  8/9/2022 3:11:14 PM  by

Paul777333


 In response to msg 19599 by  ddon158
view thread

Re: Anything exciting on the conference call?

 I listened to most of the call, not all, but my sense was they were stressing their remaining pipeline.  Oh and by the way, the stopped the last existing pain trial so one less pipeline item.  
 
I think the stock is trading at its value with the assumption that the Trofinetide will be approved.  I see the potential for the stock to hit $30 with approval of Trofinetide considering Acadia would then be profitable.
 
The only other significant pipeline item is the negative symptoms of Schizophrenia.  I have high hopes for this indication.  Having said that, assuming positive results come out in 2023 and assuming 1 year till approval (2024), I would think we only have a few years left of patent.
 
They also mentioned other early stage drugs, but they are so far off I wouldn't put much value in them.  Just my 2 cents.
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 7  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
19601 Thanks for the update. I think its holding up pretty well, I thought wed have a bloodbath. ddon158 1 8/9/2022 3:55:26 PM




Financial Market Data provided by
.
Loading...